3 weeks on semaglutide results are in! 👏🏼😍 Our beautiful patient just completed months of our medically supervised weight loss program. Over the last 90 days she has continued to exercise and eat a 3 months on semaglutide –

Mortality and renal disease in type 1 diabetes mellitus progress made, more to be done

Aronnes clinical trial for orforglipron, the rate of adverse events (meaning health issues that happened during the trial, including things likely not related to the drug itself) appeared to be slightly lower than whats seen with injectables

We also explore the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, amylin mimetics, leptin analogues, ghrelin antagonists and centrally acting agents to suppress appetite [neuropeptide Y (NPY) antagonists, melanocortin-4 receptor (MC4R) agonists and cannabinoid-1 receptor antagonists]

Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies

The goal is to achieve better and longer-lasting weight management results